Indeed, a prior study demonstrated the critical role of CXCR4 inhibition post-RT: A three-week course of AMD3100 treatment was more effective in inhibiting tumor growth when used after versus concurrently with a three-week regimen of fractionated RT with cisplatin [32]. The gene discussed is CXCR4; the disease is neoplasm.